Theoretically, therefore, if NRF2 can inhibit DOX sensitivity within cancers by interfering with senescence pathways, it could be postulated that this pathway could be applied within the cardiovascular system to alleviate DOX-induced cardiac senescence and off-target cardiotoxicity. Here, NFE2L2 is linked to cancer.